{"id":"NCT01084876","sponsor":"Celltrion","briefTitle":"Demonstrate Efficacy and Safety of Metastatic Breast Cancer","officialTitle":"A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination With Paclitaxel, in Patients With Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2012-07","completion":"2015-03","firstPosted":"2010-03-11","resultsPosted":"2025-02-11","lastUpdate":"2025-02-11"},"enrollment":475,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Breast Cancer"],"interventions":[{"type":"DRUG","name":"CT-P6","otherNames":[]},{"type":"DRUG","name":"Herceptin","otherNames":["Trastuzumab"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]}],"arms":[{"label":"CT-P6 & Paclitaxel","type":"EXPERIMENTAL"},{"label":"Herceptin & Paclitaxel","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to demonstrate equivalence","primaryOutcome":{"measure":"Objective Response Rate","timeFrame":"6 months (up to 24 weeks)","effectByArm":[{"arm":"CT-P6","deltaMin":138,"sd":null},{"arm":"Herceptin","deltaMin":143,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":244},"commonTop":["Alopecia","Neutropenia","Neuropathy peripheral","Peripheral sensory neuropathy","Myalgia"]}}